

PROVIDER BULLETIN

PROVIDER INFORMATION



November 1, 2023

Medical Policy Updates: Coupe Health and Self-Funded Benefit Plans managed by Blue Cross and Blue Shield of Alabama

Participating providers are invited to submit for consideration scientific, evidence-based information, professional consensus opinions, and other information supported by medical literature relevant to our draft policies for Coupe Health and Self-Funded benefit plans managed by Blue Cross and Blue Shield of Alabama.

The draft policies are available for physician comment for 45 days from the posting date found on the document. At the conclusion of the 45 days, policies will go into effect. Make sure your voice is heard by providing feedback directly to us.

How to Submit Comments on Draft Medical Policies

[Complete our medical policy feedback form](https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback) online at <https://mn-policies.exploremyplan.com/portal/web/mn-policies/feedback> or send comments and supporting documentation to us by mail or fax:

Birmingham Service Center
Attn: Health Management - Medical Policy
P.O. Box 10527
Birmingham, AL 35202
Fax: 205-220-0878

Draft Medical Policies

Draft medical policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/guidelines)

Policy #	Policy Title
MP-203	Home Non-Invasive Positive Airway Pressure Devices for the Treatment of Respiratory Insufficiency and Failure
MP-714	Diaphragmatic/Phrenic Nerve Stimulation and Diaphragm Pacing
MP-748	Remote Electrical Neuromodulation for Migraines
MP-754	Annular Closing Device

Draft Provider-Administered Drug Policies

Draft provider-administered drug policies can be found at [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/guidelines) and [Policies & Guidelines \(exploremyplan.com\)](https://mn-policies.exploremyplan.com/portal/web/mn-policies/guidelines)

Policy #	Policy Title
PH-90721	Izervay (avacincaptad pegol)
PH-90727	Veopoz (pozelimab-bbfg)
PH-90026	Aflibercept: Eylea, Eylea HD
PH-90017	Benlysta_IV (belimumab)
PH-90027	Cerezyme (imiglucerase)
PH-90635	Dextenza (dexamethasone insert)
PH-90105	Elelyso (taliglucerase alfa)
PH-90133	Natalizumab (Tysabri, Tyruko)
PH-90614	Saphnelo (anifrolumab-fnia)
PH-90114	Soliris (eculizumab)
PH-90427	Ultomiris (ravulizumab-cwvz)
PH-90141	VPRIV (velaglucerase alfa)
PH-90649	Vyvgart_IV (efgartigimod alfa-fcab)
PH-90712	Vyvgart_SQ (efgartigimod alfa and hyaluronidase-qvfc)